BR112014023321A2 - Composições compreendendo fagos antibacterianos e seus usos - Google Patents

Composições compreendendo fagos antibacterianos e seus usos

Info

Publication number
BR112014023321A2
BR112014023321A2 BR112014023321A BR112014023321A BR112014023321A2 BR 112014023321 A2 BR112014023321 A2 BR 112014023321A2 BR 112014023321 A BR112014023321 A BR 112014023321A BR 112014023321 A BR112014023321 A BR 112014023321A BR 112014023321 A2 BR112014023321 A2 BR 112014023321A2
Authority
BR
Brazil
Prior art keywords
infections
diabetic foot
compositions
directed
treatment
Prior art date
Application number
BR112014023321A
Other languages
English (en)
Other versions
BR112014023321B1 (pt
Inventor
Isabel Rodrigues Leandro Clara
João Duarte Alves Mendes João
Volker Côrte-Real Sofia
Original Assignee
Technophage Investig E Desenvolvimento Em Biotecnologia Sa
Tecnifar Ind Tecnica Farmaceutica S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technophage Investig E Desenvolvimento Em Biotecnologia Sa, Tecnifar Ind Tecnica Farmaceutica S A filed Critical Technophage Investig E Desenvolvimento Em Biotecnologia Sa
Publication of BR112014023321A2 publication Critical patent/BR112014023321A2/pt
Publication of BR112014023321B1 publication Critical patent/BR112014023321B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/32—Surgical cutting instruments
    • A61B17/3205—Excision instruments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/32—Surgical cutting instruments
    • A61B2017/320004—Surgical cutting instruments abrasive
    • A61B2017/320008—Scrapers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

composições compreendendo fagos antibacterianos e seus usos. a presente invenção está direcionada para a área de terapia fágica para o tratamento e controle de infecções bacterianas, em particular infecções do pé diabético. mais especificamente, a presente invenção está direcionada para novos coquetéis das cepas de bacteriófagos f44/10, f125/10, f770/05, f510/08, f1245/05, e/ou suas variantes; e métodos de uso dos mesmos no tratamento e prevenção de infecções bacterianas, incluindo úlceras cutâneas associadas a infecções do pé diabético, causadas, por exemplo, por staphylococcus aureus, pseudomonas aeruginosa, e/ou acinetobacter baumannii. os coquetéis são usados como composições farmacêuticas quer sozinhos, quer em combinação adicional com outras terapias, por exemplo, antibióticos, fatores de crescimento, ou outras terapias padrão, bem como não padrão, para infecções do pé diabético.
BR112014023321-7A 2012-03-19 2013-03-19 Composições compreendendo fagos antibacterianos e seus usos BR112014023321B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261612531P 2012-03-19 2012-03-19
US61/612,531 2012-03-19
PCT/PT2013/000016 WO2013141730A1 (en) 2012-03-19 2013-03-19 Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
BR112014023321A2 true BR112014023321A2 (pt) 2022-02-01
BR112014023321B1 BR112014023321B1 (pt) 2022-06-14

Family

ID=48534472

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023321-7A BR112014023321B1 (pt) 2012-03-19 2013-03-19 Composições compreendendo fagos antibacterianos e seus usos

Country Status (14)

Country Link
US (1) US9962419B2 (pt)
EP (1) EP2833899B1 (pt)
JP (1) JP6186427B2 (pt)
CN (1) CN104519893B (pt)
AU (1) AU2013235883B2 (pt)
BR (1) BR112014023321B1 (pt)
CA (1) CA2867418C (pt)
DK (1) DK2833899T3 (pt)
ES (1) ES2814024T3 (pt)
HK (1) HK1207002A1 (pt)
PT (1) PT2833899T (pt)
RU (1) RU2654596C2 (pt)
SG (1) SG11201405829WA (pt)
WO (1) WO2013141730A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2865383A1 (en) * 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
WO2016066722A2 (en) * 2014-10-28 2016-05-06 Ian Humphery-Smith Bacteriophage combinations for human or animal therapy
US10455983B2 (en) 2015-09-10 2019-10-29 Prince Castle LLC Modular food holding system
US20170157186A1 (en) * 2015-12-02 2017-06-08 Smart Phage, Inc. Phage to treat bacteria on skin
US11554158B2 (en) 2016-04-13 2023-01-17 Northeast Ohio Medical University GPNMB compositions for treatment of skin wounds
CA3045284A1 (en) * 2016-12-05 2018-06-14 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof
WO2019050902A1 (en) * 2017-09-05 2019-03-14 Adaptive Phage Therapeutics, Inc. METHODS OF DETERMINING THE SENSITIVITY PROFILE OF A BACTERIAL STRAIN TO A THERAPEUTIC COMPOSITION
CA3079544A1 (en) * 2017-10-19 2019-04-25 Mona E. Buice Topical composition for improved healing of open wounds
CN111448616A (zh) 2017-12-11 2020-07-24 自适应噬菌体治疗公司 噬菌体分配系统
EP3735275A1 (en) * 2018-01-02 2020-11-11 Armata Pharmaceuticals, Inc. Therapeutics bacteriophage compositions for treating staphylococcus infection
CN109082414B (zh) * 2018-06-29 2020-11-13 浙江工业大学 一种金黄色葡萄球菌噬菌体及应用
CN112672788A (zh) 2018-07-24 2021-04-16 免疫医疗有限责任公司 抗金黄色葡萄球菌凝集因子a(clfa)的抗体
CN109730235A (zh) * 2019-02-01 2019-05-10 珠海横琴普罗恩能医用食品有限公司 一种用于医用食品的防腐剂
US20220233615A1 (en) * 2019-05-21 2022-07-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bacteriophages for the treatment of tuberculosis
CN111643724B (zh) * 2020-07-01 2022-01-28 南京大学 一种载有噬菌体和酸性成纤维细胞生长因子的水凝胶伤口敷料的制备方法及其应用
WO2022013318A1 (en) 2020-07-14 2022-01-20 Biontech R&D (Austria) Gmbh New mosaic bacteriophages and uses thereof
WO2022013314A1 (en) 2020-07-14 2022-01-20 Biontech R&D (Austria) Gmbh Bacteriophage cocktails and uses thereof
CN112251439B (zh) * 2020-10-26 2022-06-21 齐鲁师范学院 拟南芥高温诱导启动子pHTG1及其重组载体
CN112301001B (zh) * 2020-11-03 2022-10-14 华中农业大学 金黄色葡萄球菌噬菌体lsa2311及其应用
CN113201458B (zh) * 2020-12-21 2022-05-27 青岛诺安百特生物技术有限公司 一种提高噬菌体制剂稳定性的组合物及其应用
EP4337764A1 (en) * 2021-05-12 2024-03-20 Biomx Ltd. Staphylococcus bacteriophage and uses thereof
DE202022102100U1 (de) 2022-04-20 2022-04-27 Prabhakar Ramesh Bhandari Synergistische antibiotische pharmazeutische Zusammensetzung zur Behandlung von Staphylococcus aureus-Infektionen
WO2024115430A1 (en) * 2022-11-28 2024-06-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Acinetobacter baumannii phages

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995027043A1 (en) 1994-04-05 1995-10-12 Exponential Biotherapies, Inc. Antibacterial therapy with genotypically modified bacteriophage
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US6138401A (en) 1999-06-25 2000-10-31 Duncan; Franklin R. Fish hook remover
CN1643139A (zh) * 2002-03-25 2005-07-20 沃里克大学 抗菌剂
US20050095222A1 (en) 2003-10-29 2005-05-05 Taro Suzuki Allergen inhibitor, allergen-inhibiting method, allergen-inhibiting fiber and allergen-inhibiting sheet
DK1812025T3 (da) 2004-11-02 2012-10-22 Chr Hansen As Stabiliserede bakteriofagformuleringer
EP1833497A4 (en) 2004-11-02 2009-11-11 Cangagen Life Sciences Inc BACTERIOPHAGE COMPOSITIONS
CA2593992A1 (en) 2004-12-06 2006-06-15 Rodney M. Donlan Inhibition of biofilm formation using bacteriophage
AU2006251827B2 (en) 2005-05-26 2012-05-31 Chr. Hansen A/S Bacterial management in animal holding systems
ES2761835T3 (es) 2009-02-06 2020-05-21 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Fagos antibacterianos, péptidos de fagos y métodos de uso de los mismos
PT104837A (pt) 2009-11-24 2011-05-24 Technophage Investiga O E Desenvolvimento Em Biotecnologia S A P?ptidos de fagos enteroc?cicos e m?todos para a sua utiliza??o
CA3154006A1 (en) * 2010-09-17 2012-03-22 Technophage, Investigacao E Desenvolvimento Em Biotecnologia S.A. Antibacterial phage, phage peptides and methods of use thereof

Also Published As

Publication number Publication date
RU2014141941A (ru) 2016-05-20
JP6186427B2 (ja) 2017-08-23
CN104519893B (zh) 2020-02-07
AU2013235883B2 (en) 2018-01-04
EP2833899A1 (en) 2015-02-11
CN104519893A (zh) 2015-04-15
ES2814024T3 (es) 2021-03-25
WO2013141730A1 (en) 2013-09-26
AU2013235883A1 (en) 2014-10-02
RU2654596C2 (ru) 2018-05-21
BR112014023321B1 (pt) 2022-06-14
JP2015512384A (ja) 2015-04-27
PT2833899T (pt) 2020-09-15
SG11201405829WA (en) 2014-10-30
EP2833899B1 (en) 2020-06-24
HK1207002A1 (en) 2016-01-22
US9962419B2 (en) 2018-05-08
US20150150919A1 (en) 2015-06-04
DK2833899T3 (da) 2020-09-28
CA2867418C (en) 2020-03-10
CA2867418A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
BR112014023321A2 (pt) Composições compreendendo fagos antibacterianos e seus usos
BR112019011660A2 (pt) composições de bacteriófagos que compreendem fagos antibacterianos respiratórios e métodos de uso das mesmas
BR112017004889A2 (pt) uso antibacteriano de salicilanilidas halogenadas
BR112015014458A8 (pt) compostos derivados de manose, seus intermediários, composição, uso e processos de preparação
BR112013032974A2 (pt) "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas".
BR112014004515A2 (pt) "compostos antibacterianos, seu uso, composição farmacêutica e combinação terapêutica que os compreende"
BR112015016001A2 (pt) compostos, composições farmacêuticas e respectivos usos e método para tratar ou prevenir infecção bacteriana
BR112015003592A2 (pt) derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
WO2012036580A3 (en) Antibacterial phage, phage peptides and methods of use thereof
BR112018068593A2 (pt) composições tópicas não aquosas que compreendem uma salicilanilida halogenada
BR112013028813A2 (pt) derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
BR112015029367A2 (pt) terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas
BR112014026058A2 (pt) composições para tratamento tópico de infecções microbianas
BR112017020935A2 (pt) ?compostos, composição farmacêutica e conjunto?
BR112012030029A2 (pt) beta-lactamases modificadas e métodos e usos relacionados a elas
BR112014018421A8 (pt) Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas
BR112012027197A2 (pt) combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas
BR112016016854A2 (pt) Derivados de 7-oxo-1,6-diazabiciclo[3.2.1]octana, seu processo de preparação e seu uso, composição farmacêutica e seu uso pedidos de patente relacionados
BR112016009062A2 (pt) Composição antibacteriana, método para a preparação de uma composição, método para prever ou determinar a eficácia de uma terapia de bacteriófago em um indivíduo, método para selecionar um indivíduo ou determinar se um indivíduo é susceptível de se beneficiar de uma terapia com bacteriófagos, bacteriófago, ácido nucleico isolado, e, polipeptídeo isolado
BR112015024939A2 (pt) composto, diastereoisômero ou epímero de um composto, composição farmacêutica, uso de um composto, processo para a preparação de um composto, e, método para tratamento de uma infecção
BR112022007926A2 (pt) Composições de cocktail que compreendem fagos antibacterianos respiratórios e métodos de utilização das mesmas
BR112015001619A2 (pt) manosídeos multiméricos, um processo para a preparação dos mesmos e as suas utilizações como um medicamento
BR112017020796A2 (pt) compostos, composição farmacêutica e kit
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: TECNIFAR-INDUSTRIA TECNICA FARMACEUTICA, S.A. (PT) ; TECHNOPHAGE, INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA (PT)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870210072651 DE 09/08/2021, E NECESSARIO APRESENTAR A GUIA DE RECOLHIMENTO REFERENTE AO SERVICO SOLICITADO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA, VISTO QUE NAO HOUVE COMPROVACAO DE PAGAMENTO APOS 10 DIAS.

B25C Requirement related to requested transfer of rights

Owner name: TECNIFAR-INDUSTRIA TECNICA FARMACEUTICA, S.A. (PT) ; TECHNOPHAGE, INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA (PT)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 870210072662 DE 09/08/2021, E NECESSARIO APRESENTAR DOCUMENTO NOTARIZADO E COM APOSTILAMENTO OU LEGALIZACAO CONSULAR. ALEM DISSO, E PRECISO APRESENTAR A GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25A Requested transfer of rights approved

Owner name: TECHNOPHAGE, INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA (PT)

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/03/2013, OBSERVADAS AS CONDICOES LEGAIS